Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.
Jianda Yuan, Jedd D. Wolchok(Cornell University), Gregor Manukian(Memorial Sloan Kettering Cancer Center), Stephanie Terzulli(Memorial Sloan Kettering Cancer Center), Shachi Vyas(University of Pittsburgh), Francesca Orlandi, Susan E. Krown(Memorial Sloan Kettering Cancer Center), Geoffrey Y. Ku(Memorial Sloan Kettering Cancer Center), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Zhenyu Mu, Lloyd J. Old(Gynecologic Oncology Group), Hao Li(Tianjin Medical University General Hospital), Yinyan Xu, Alan N. Houghton(Eastern Cooperative Oncology Group), Katherine S. Panageas(Mayo Clinic), Humilidad F. Gallardo(Memorial Sloan Kettering Cancer Center), Teresa Rasalan
PubMed
June 5, 2009
Cited by 80
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k